Weibond Technology

Weibond Technology established itself as China’s pioneer in intravenous (IV) compounding automation, developing robotic systems that prepare sterile IV medications in hospital pharmacies. Since 2009, the company has focused exclusively on pharmacy IV compounding automation, accumulating 199 patents and deploying systems across major Chinese hospitals including Shanghai Jiaotong University Renji Hospital and Sichuan Provincial People’s Hospital.

Company Overview

Founded in Shenzhen in 2009, Weibond Technology (深圳市卫邦科技有限公司) specializes in research, development, manufacturing, and service of robotic products for pharmacy IV compounding. The company maintains a strong R&D orientation, with 61% of its workforce engaged in research and development activities. All 199 patents are fully owned by the company, reflecting complete intellectual property independence.

Weibond positions itself as both the pioneer and market leader in China’s pharmacy IV compounding automation sector. The company’s WEINAS (Weibond Intravenous Assistant System) product line represents the first domestically developed IV compounding robot system to achieve commercial deployment in Chinese hospitals.

Core Products

WEINAS PD-160 Series

The flagship WEINAS PD-160 series is the world’s first IV compounding robot compatible with both vials and ampoules, addressing the unique requirements of Chinese hospital pharmacies where both container types are commonly used. The system provides fully automatic, programmable IV compounding with thorough in-process quality control.

WEINAS VD-160 Series

The WEINAS VD-160 series offers similar functionality to the PD-160 but is designed specifically for vial-based medications. This system requires less floor space and represents a cost-effective option for facilities that primarily use vial containers.

Technology & Innovation

Weibond’s WEINAS systems incorporate several key technologies for safe and accurate IV preparation:

• ISO Class 5 Environment: HEPA-certified air filtration maintains continuous sterile conditions throughout the compounding process
• Dual Verification: Image recognition and barcode scanning verify order details and ingredients before compounding
• Patented Liquid Transfer: Proprietary liquid transfer technology minimizes particulate contamination risk
• Video Documentation: Multiple cameras record the entire compounding procedure for quality assurance and traceability
• Gravimetric Verification: Precision weighing confirms dose accuracy during preparation

Research published in peer-reviewed journals has demonstrated that WEINAS robotic compounding significantly reduces environmental contamination compared to manual preparation in biological safety cabinets. Studies show surface contamination on infusion bags during robotic compounding is up to 23 times lower for certain hazardous drugs compared to manual methods.

Market Presence

Weibond’s systems are deployed in major tertiary hospitals across China, with documented installations at Shanghai Jiaotong University School of Medicine Renji Hospital, Sichuan Provincial People’s Hospital, and other institutions. The company participated in the 2018 ASHP Midyear Clinical Meeting in the United States, becoming the first Chinese company to exhibit IV compounding robots at this major pharmacy conference.

The company competes in a global market that includes established players such as Arxium (RIVA system), Omnicell, Grifols, and Loccioni (APOTECAchemo). In China, Weibond faces competition from companies including Shanghai Will Information Technology and Shenzhen Sanggu Medical Robot.

Key Milestones

• 2009: Company founded in Shenzhen
• 2016: First clinical deployment of WEINAS systems in Chinese hospitals
• 2018: Global product launch at ASHP Midyear Clinical Meeting, first Chinese IV robot company at the event
• Present: 199 patents accumulated with 100% IP ownership

Frequently Asked Questions

What types of IV preparations can WEINAS handle?

WEINAS systems can prepare both hazardous and non-hazardous IV medications, including chemotherapy drugs. The PD-160 series handles both vial and ampoule containers, while the VD-160 series is designed for vials only.

How does WEINAS improve pharmacy safety?

The robotic system removes human operators from direct exposure to hazardous drugs during compounding. Studies demonstrate significantly reduced environmental contamination compared to manual preparation, protecting pharmacy staff from occupational exposure.

Is Weibond Technology publicly traded?

No, Weibond Technology is a privately held company. No public stock listing has been announced.